Ruxolitinib, a JAK1/2 inhibitor Food and Drug Administration (FDA) approved for MF patients and for PV patients intolerant or resistant to hydroxyurea, has anti-inflammatory properties and its administration has been correlated with reductions in plasma levels of C reactive Protein (CRP), interleukin-1 receptor-alpha (IL-1Rα), Macrophage Inflammatory Protein-1-beta (MIP-1β), Tumor Necrosis Factor-alpha (TNF-α) and interleukin-6 (IL-6) (8). This evidence concerns the gene CCL4 and acquired polycythemia vera.